CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
Clinical Trials
0
0 active
Approvals
45
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- A 2nd U.S. Circuit Court of Appeals panel revived portions of nationwide litigation alleging drugmakers sold billions of dollars in oral phenylephrine decongestants that were no better than placebo. - The court allowed claims over "maximum strength" labeling and brand-name drugs approved through the New Drug Application process to proceed, while preempting most state law-based claims. - An FDA advisory panel concluded in September 2023 that oral phenylephrine was ineffective as a decongestant, and the FDA proposed removing the ingredient from OTC cold medications in November 2024. - Circuit Judge Denny Chin acknowledged the apparent unfairness but stated the remedy "must flow not from litigation but from the FDA."
- Sanofi has confirmed intermittent supply issues for Lantus SoloStar insulin glargine pens in the U.S., driven by increased demand and broader market dynamics. - The supply disruption is limited to the SoloStar pen formulation; Lantus U-100 vials and Toujeo U-300 remain available as alternatives. - Patients in North Carolina and elsewhere report difficulty refilling prescriptions, with CVS acknowledging supply challenges over the past several months. - Sanofi is accelerating production and expediting replenishment stock but cannot provide a definitive timeline for a full return to normal supply levels.
- UVA researchers analyzed 352 over-the-counter probiotic products from major U.S. pharmacy chains and found only 36 unique bacterial species, with no consistency in formulations linked to health claims. - The team developed HaPaPro, a collection of over 1,000 computer models of bacterial metabolism, to rationally design microbiome-targeted therapies. - Using HaPaPro, researchers successfully identified microbes with potential to prevent bacterial vaginosis, demonstrating the platform's therapeutic promise. - Findings published in Nature Microbiology highlight how computational modeling could lead to evidence-based probiotic products that deliver on their marketed health promises.
- Walmart, Costco, Amazon, and CVS are leveraging direct-to-consumer GLP-1 programs to capture patients losing employer-sponsored coverage for weight-loss drugs like Wegovy and Zepbound. - A Mercer survey shows 6% of large employers dropped GLP-1 coverage this year, with the drugs' share of claims swelling to 11.4% from 6.9% in 2023. - Retailers view GLP-1 prescriptions as a gateway to recurring customer relationships, with pharmacy visits driving grocery and merchandise sales across their networks. - Independent pharmacies face significant disadvantages, raising safety concerns about drug interaction monitoring when patients fill GLP-1 prescriptions at multiple locations.
- A U.S. jury found Takeda Pharmaceutical liable for $885 million in damages for delaying generic competition of constipation drug Amitiza through an anticompetitive scheme. - The verdict marks the first time a pharmaceutical company has been found liable by a jury in class action litigation over pay-for-delay agreements since the 2013 Supreme Court ruling. - Under federal antitrust law, the $885 million award could be automatically tripled to several billion dollars, representing a significant financial penalty for the Japanese drugmaker. - The case centered on a 2014 settlement where Takeda allegedly paid Par Pharmaceutical $210 million to delay launching generic lubiprostone until January 2021, postponing competition by six years.
- K.C. Pharmaceuticals voluntarily recalled 3,111,072 bottles of over-the-counter eye drops in early March after the FDA cited a "lack of assurance of sterility." - The recalled products include multiple formulations sold under various brand names at major retailers including CVS, Walgreens, Rite Aid, Kroger, and other pharmacy chains. - The FDA classified this as a Class II recall, indicating the products may cause temporary or medically reversible adverse health consequences. - No injuries have been reported yet associated with the recalled eye drops, though consumers are advised to stop using affected products and contact retailers for refunds.
- ACON Laboratories launched the Flowflex Plus RSV + Flu A/B + COVID 4-in-1 test, marking the first FDA-cleared home diagnostic capable of detecting four major respiratory infections with a single nasal swab. - The test represents a breakthrough for pediatric care as the first respiratory home test cleared for use in children as young as six months, addressing critical RSV detection needs. - Early identification capabilities are particularly significant since RSV is the leading cause of hospitalization in young children according to the CDC. - The test is now available nationwide at major retailers including CVS, Walgreens, and Albertsons, supporting faster decision-making for families managing respiratory symptoms.
- TempraMed Technologies has launched VIVI Cap Smart, the world's first platform that combines temperature protection with digital tracking for insulin and GLP-1 pens. - The device integrates proprietary space-grade thermal insulation technology with digital health functionality, enabling automatic injection timing tracking and medication logging through a connected mobile application. - This launch represents TempraMed's strategic transition toward a comprehensive patient platform that combines physical device innovation with digital tools for chronic disease management. - The company has already achieved significant commercial traction with over 120,000 devices sold globally and distribution through major retailers and healthcare organizations including Maccabi Healthcare Services.
- Eli Lilly's tirzepatide franchise, including Zepbound and Mounjaro, generated $10.1 billion in Q3 2024, overtaking Merck's Keytruda as the world's best-selling drug for the first time. - The company reported a remarkable 54% year-over-year revenue increase to $17.6 billion in Q3, driven by 62% volume growth in its GLP-1 medications despite price declines. - Lilly raised its full-year revenue forecast to $63-63.5 billion from the previous $60-62 billion estimate, reflecting strong performance in the rapidly expanding obesity and diabetes treatment market. - The pharmaceutical giant is implementing direct-to-consumer strategies through LillyDirect, offering Zepbound at reduced prices to address affordability concerns and maintain market leadership.
- Cumberland Pharmaceuticals and RedHill Biopharma announced a strategic partnership to jointly commercialize Talicia, an FDA-approved treatment for Helicobacter pylori infection in adults. - The companies will form a jointly owned entity with Cumberland providing $4 million in investment capital and assuming distribution responsibilities for the product that generated $8 million in net revenues in 2024. - Talicia is the only all-in-one treatment combining omeprazole, amoxicillin, and rifabutin, achieving >90% eradication rates and now listed as a first-line option in updated American College of Gastroenterology guidelines. - The product benefits from patent protection through 2042, eight years of market exclusivity under QIDP designation, and broad insurance coverage including 70% of commercial plans and 60% of government plans.
